Shots:
Mabwell has signed licensing and commercialization agreements with local partners in the Philippines, Vietnam, and Malaysia for its aflibercept biosimilar, a biosimilar version of Eylea
As per the deal, Mabwell and its partners jointly advance the product’s registration and commercialization in these markets
Aflibercept is a VEGF inhibitor approved for the treatment of Neovascular (wet) age-related macular…
